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Abstract
Background: Cytotoxic T Lymphocytes (CTL) recognize complexes of peptide ligands and Major Histocompatibility Complex
(MHC) class I molecules presented at the surface of Antigen Presenting Cells (APC). Detection and isolation of CTL’s are of
importance for research on CTL immunity, and development of vaccines and adoptive immune therapy. Peptide-MHC
tetramers have become important reagents for detection and enumeration of specific CTL’s. Conventional peptide-MHC-
tetramer production involves recombinant MHC production, in vitro refolding, biotinylation and tetramerization; each step
followed by various biochemical steps such as chromatographic purification, concentration etc. Such cumbersome
production protocols have limited dissemination and restricted availability of peptide-MHC tetramers effectively precluding
large-scale screening strategies involving many different peptide-MHC tetramers.
Methodology/Principal Findings: We have developed an approach whereby any given tetramer specificity can be
produced within 2 days with very limited effort and hands-on time. The strategy is based on the isolation of correctly
oxidized, in vivo biotinylated recombinant MHC I heavy chain (HC). Such biotinylated MHC I HC molecules can be refolded in
vitro, tetramerized with streptavidin, and used for specific T cell staining-all in a one-pot reaction without any intervening
purification steps.
Conclusions/Significance: We have developed an efficient ‘‘one-pot, mix-and-read’’ strategy for peptide-MHC tetramer
generation, and demonstrated specific T cell straining comparable to a commercially available MHC-tetramer. Here, seven
peptide-MHC tetramers representing four different human MHC (HLA) class I proteins have been generated. The technique
should be readily extendable to any binding peptide and pre-biotinylated MHC (at this time we have over 40 different pre-
biotinylated HLA proteins). It is simple, robust, and versatile technique with a very broad application potential as it can be
adapted both to small- and large-scale production of one or many different peptide-MHC tetramers for T cell isolation, or
epitope screening.
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Introduction
Antigen-specific, MHC-restricted T cells (hereafter referred to as
‘‘specific T cells’’) play many important roles in the generation of
immune responses. It is therefore important to be able to identify,
enumerate and characterize specific T cells, e.g. during infections,
vaccinations or immunotherapies. In the past, assays of proliferation,
cytotoxicity, and/or bulk cytokine production have been used as
functional evidence of the presence of specific T cells. Combined
with laborious limiting dilution experiments, these assays have even
provided indirect measurements of the frequency of specific T cells.
More recent and less cumbersome assays have detected and counted
specific T cellresponses at the single cell level using either ELISPOT
assays of cytokine release [1–4], or flow cytometry-based assays for
intracellular cytokine production [5]. These assays, however, are still
based upon functionalassays andthefrequencyofresponding T cells
may not necessarily be the same as the frequency of T cells
expressing the appropriate T cell receptor [6]. In a 1996 landmark
achievement, Altman and co-workers [7] generated fluorescence
labeled, peptide-MHC multimers of defined specificity (generally
known in the field of T cell immunology as ‘‘MHC tetramers’’) and
demonstrated their ability to stain specific T cells. They surmised
that peptide-MHC multimers would engage several of the T cell
receptors expressed on a specific T cell surface and stabilize an
otherwise very short lived interaction, thus allowing direct and
specific staining of the T cell. Whereas functional assays involves
some kind of re-stimulation, MHC tetramers can be used to identify
specific T cells without further in vitro manipulation, and they allow
for a simultaneous evaluation of the differentiation state through co-
staining for various cell surface differentiation markers. In addition,
MHC tetramers can be used to purify [8], manipulate, and stimulate
[9,10] specific T cells.
Thus, MHC tetramers provide a simple, fast and efficient
approach for monitoring and handling specific T cells. Unfortu-
nately, the production of MHC tetramers is technically demand-
ing. The Altman tetramer production can be sub-divided into
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peptide-MHC monomer production, biotinylation of peptide-
MHC monomers, and finally addition of fluorescent labeled
streptavidin to effect tetramerization. After each of these steps, the
product has to be processed biochemically (e.g. purified by column
chromatography, concentrated etc.) before being subjected to the
next step. This need for a biochemical set-up and proficiency limits
the dissemination of the technology and effectively prevents the
application of MHC tetramers to large-scale analysis and use.
Indeed, the NIH has created a core facility to generate MHC
tetramers; however, the use of the NIH MHC tetramer facility
requires approval and may be limited.
We have previously generated pre-oxidized recombinant MHC
class I molecules of a quality that allows virtually complete folding
and peptide-MHC complex formation[11]. Here, we have gener-
atedfullypre-biotinylated versionsofthe MHC classI molecules and
demonstrated that these can be used as convenient reagents in the
preparation of biotinylated peptide-MHC monomers. Adding
streptavidin to such MHC complexes efficiently leads to MHC
tetramer formation. Given the efficiency of our folding, biotinylation
and tetramerization processes, we reasoned that it might be possible
to omit most, if not all, of the preparative biochemical work involved
in tetramer production and create a ‘‘one-pot, mix-and-read’’
protocol. In this scenario, recombinant, pre-biotinylated MHC
molecules would be successively reacted with peptide, streptavidin
and eventually T cells without any intervening purification or
concentration processes. Indeed, we have developed several
examples of such ‘‘one-pot, mix-and-read’’ tetramers and demon-
strated specific T cell staining of a quality fully comparable with a
commercially available counterpart. Pre-oxidized and pre-biotiny-
lated MHC class I heavy chainmolecules could be produced inlarge
quantities for wide distribution to laboratories, where they could be
readily used to generate tetramers with peptides of choice. Thus, this
tetramer technology could allow virtually any end-user to generate
his or hers own MHC tetramers at will, and it should allow large-
scale MHC tetramer screening approaches.
Results and Discussion
Production of recombinant biotinylated MHC-I heavy
chains
To assure one single specific biotinylation of each recombinant
MHC molecule, a biotinylation substrate peptide (BSP) sequence
specific for the E.coli biotin protein ligase, BirA, enzyme was
attached to the C-terminal end of the recombinant MHC-I HC.
This enables specific biotinylation of MHC-I HC by BirA. For
MHC tetramer production, biotinylation of the BSP site has
mostly been based on biochemical in vitro biotinylation of the
folded MHC-I complex. This needs to be followed by chromato-
graphic purification steps, which are time consuming and
potentially associated with significant loss of material. Induction
of efficient in vivo biotinylation of the HC would therefore save
both time and material. The endogenous BirA expression in E. coli
is insufficient for an efficient biotinylation of over-expressed
proteins. However, co-expression of the BirA enzyme either in the
E. coli or insect cell expression systems has been shown to increase
the biotinylation efficiency[12,13]. Therefore, the BL21 (DE3) E.
coli strain was co-transformed with a pET28a+ vector encoding
the MHC-I HC-BSP and a pASYC vector encoding the BirA
enzyme. Production of HC and BirA were induced by addition of
IPTG for the last 3 h of culture (Figure 1A). Biotin was added to
the bacterial culture immediately before induction of expression of
HC and BirA. The biotinylation efficiency of the HC was
evaluated in a SDS-PAGE gel-shift assay. Samples of HC were
incubated with increasing amount of Streptavidin (SA), and
subsequently separated by SDS-PAGE. Biotinylated HC will bind
to SA and thereby significantly increase the molecular weight of the
complex. This resulted in disappearance of the HC-band and
appearance of bands of higher molecular weights (Figure 1B). Using
densitometry, the residual HC-band representing the non-biotiny-
lated HC were quantified and compared to the total amount of HC
(lane without SA added). We have produced and analyzed 27 HLA-
A alleles and 14 HLA-B alleles this way, and in all cases obtained
biotinylation efficiencies in the range of 85–100% (Table 1). More
than L of these preparations were more than 95% biotinylated the
rest were between 82 and 94% biotinylated. Thus, the in vivo
biotinylation procedure was highly efficient.
Biological activity of biotinylated MHC-I
To ensure that the in vivo biotinylation did not affect the
specificity and subsequent folding of the MHC class I complex, we
compared the peptide binding affinities of HLA-HLA-A*0201-
HAT-BSP with and without biotinylation to the unmodified
recombinant HLA-A*0201. A panel of small pox peptides
representing good binders of KD,10 nM (YLDYDTIYV,
FLRDNLYHV, and YLSDSAINI), intermediate binders of KD
10-100 nM (YLSTERDHV and FLETDAGRV), and non
binding peptides of KD.1 mM (ALSDACKKI), were analyzed
for binding affinity to each of HLA-A*0201 HC constructs. The
HLA-A*0201 constructs were folded in the presence of ß2m and a
titration of the peptides and the KD of each combination was
determined in a quantitative ELISA assay [14] (Figure 2). Each
peptide, strong as well as poor binders, gave essentially the same
KD value for all three HLA-A*0201 constructs. Thus, neither the
addition of the BSP site nor the biotinylation prior to folding
affected the binding specificity of the HLA-A*0201 molecule.
Refolding efficiency
In addition to a high biotinylation frequency, our approach also
depends upon a high refolding efficiency. To this end we have
exploited two previous observations; the first demonstrating that
denatured class I MHC heavy chains with pre-oxidized disulfide
bonds efficiently refold (when provided with b2m and an
appropriate peptide)[15], and the second demonstrating that the
efficiency of this process can be further improved by purification of
denatured heavy chain molecules with correct disulfide confor-
mations[11]. Thus, we have previously shown that subspecies of
correctly oxidized recombinant denatured MHC-I HC can be
purified from the inclusion bodies, and that these upon dilution
folds into functional complex with a .90% efficiency[11]. In this
paper, we have used 4 different MHC-I HC preparations for
tetramer production: HLA-A*0101, HLA-A*0201, HLA-B*0702,
and HLA-B*4402. These HC’s were in vivo biotinylated, purified,
and subsequently folded in the presence of a relevant peptide,
pp65363–373, pp65495–503, pp65417–426, and EBNA3b657–666 re-
spectively. These complexes were titrated and measured in a
quantitative ELISA. The folding efficiency was determined by
comparison to a standard of known complex concentration. As
seen in Table 1, we obtain 95–100% correctly folded complex and
these HC were 97–100% biotinylated. Note, that although we
don’t know where and how these disulfide bonds are generated, we
have at this point successfully generated tetramers from HLA
preparations representing 14 different HLA alleles, and in no case
have we failed. We conclude that these molecules in principle are
ready to be tetramerized with SA without further purification.
Tetramerization of MHC and streptavidin
In order to follow the stoichiometric distribution of SA-MHC-I
complexes during the formation of peptide-MHC tetramers, the
One-Pot, Mix-and-Read Tetramer
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spiked with radioactively labeled peptide. MHC-tetramers were
the generated at different molar ratios of MHC-I and SA; and the
formations of various SA-MHC-I multimers were followed by size-
exclusion chromatography (SEC) through detection of radioactivity
(Figure 3). SA binds MHC-I at a 1 to 4 molar ratio. Gradually
increasing the SA to MHC-I ratio from MHC-I in excess to SA in
excess, saturated and unsaturated SA molecules could be generated
at different stoichiometric ratios; SA:MHC4,S A : M H C 3,S A : M H C 2,
SA:MHC, and eventually MHC monomers. Quantification of
molecular weights according to standard marker proteins showed
agreement between theoretical and empirical molecular sizes
(Figure 3). All four SA-MHC-I multimers were generated dependent
upon the ratio between SA and MHC-I. At SA to MHC-I ratio of
1:4, the tetramer form was almost quantitatively produced,
generating none of the other multimer species and only leaving a
smallfractionofnon-reactedmonomers.Thispresumablyrepresents
a small fraction of non-biotinylated HC.
Staining specific T cells using ‘‘one pot, mix and read’’
tetramers
The efficiency of the biotinylation and folding processes suggested
tousthatitshould bepossible to generate MHCtetramersina ‘‘one-
pot’’reaction omitting most, ifnotall, of thepreparativebiochemical
work normally involved in tetramer production. To analyze whether
our ‘‘one-pot’’ tetramers were able to stain specific T cells in a ‘‘mix-
and-read’’ mode, we initially selected the HLA-A*0201 restricted
dominant CMV T cell epitopes, CMV pp65495–503 peptide as model
system. CMV pp65495–503 specific T cells from healthy donors were
generated and HLA-A*0201/pp65495–503-SA-phycoerythrin (PE)
tetramers were produced as described above. The tetramers were
not concentrated nor further purified, but used directly to stain the
specific T cells.
The specificity and sensitivity of the tetramer staining were
compared to that of the commercially available HLA-A*0201/
pp65495–503 pentamers (HProImmune, www.proimmune.com)
(Figure 4). The tetramers stain about 60% of the CD8 T cells with
a baseline separation from the negative population. The same
frequency of specific T cells was detected using the commercial
pentamers.Thestaining intensityofthe tetramerswere slightlylower
than that of the pentamers (FI 1480 vs. 2042), however, the
background staining of the negative population was also lower (FI 4
vs. 10) resulting in a higher signal to noise ratio for the in-house
generated tetramers (370 vs. 202). Thus the ‘‘one-pot, mix-and-
read’’ strategy for the HLA-A*0201/pp65495–503 tetramer produc-
tion appeared to work as well as the MHC pentamer of the same
specificity.
The MHC-I monomers were produced at a rather low
concentration compared to conventional tetramer production.
These monomers were mixed with streptavidin directly, without
any concentration, to generate the tetramers. The stability, yield,
and robustness of this production strategy were of concern. We
found that the tetramers could be stored for more that 9 months at
4uC with no change in activity (data not shown). Another concern
was whether there was a lower concentration limit of monomers
needed for production of tetramers in order to give an optimal
Figure 1. Production of MHC-I heavy chains. Clones of Escherichia coli were selected for high expression of HLA-A*0201-HAT-BSP HC and BirA
enzyme and the HLA-A*0201-HAT-BSP product was tested for biotinylation efficiency. In A) Samples of the clone were withdrawn before and after
IPTG induction and analyzed on reducing SDS-PAGE. The bacterial cell pellet was resuspended in 50 mL MgCl2/SDS lysis buffer to solubilize heavy-
chain inclusion bodies. After centrifugation at 20,000 g for 2 min, 15 mL of the supernatant was loaded directly on the gel. Lane 1, protein marker;
lane 2, before induction; and lane 3 after induction with IPTG. Positions of HC monomer and BirA are shown with arrows. In B) HLA-A*0201-HAT-BSP
was tested for biotinylation efficiency by a streptavidin gel-shift assay. Purified in vivo biotinylated HLA-A*0201-HAT-BSP incubated for 20 min with
either no SA, equal amount of SA, or SA in 2-fold excess. The samples were diluted in 26Laemmli buffer and electrophoresed on a 12%
polyacrylamide gel. For the purpose of quantitative densitometric analysis the HC sample without SA was applied to the SDS-PAGE in 3 different
amounts (undiluted, 5-fold, and 25-fold diluted). The percentage of biotinylated HC was determined from the ratio of density of the monomer HC
band in the sample with excess SA compared to the band in the diluted sample without SA.
doi:10.1371/journal.pone.0001678.g001
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pp65495–503 monomers were folded at 200 nM, 100 nM and
50 nM and each mixed with streptavidin to produce tetramers.
Thus, the maximum tetramer concentration of the 200 nM
monomers was 50 nM tetramer, of the 100 nM monomers 25 nM
tetramer, and of the 50 nM monomers 12.5 nM tetramer. Two
fold titrations were made of each of these three productions and
used to stain pp65495–503 specific T cells. Baseline separation
between the positive and negative cell population was seen for all
the concentrations used. The relative fluorescence intensity is
depicted as a function of the actual tetramer concentration used to
stain the cells (Figure 5). The curves for the three-tetramer
productions were super imposable showing considerable robust-
ness in set-up and staining reactions. The actual tetramer
concentration used in the staining reaction, and not the
concentration of monomers used for the tetramer production,
was important for the staining intensity. The staining intensity
reached a plateau and the T cell labeling was saturated at tetramer
concentrations above 12.5 nM. Therefore, saturable T cell
staining can be achieved using tetramers produced from
concentration of monomers higher than 50 nM.
Unreacted monomers do not inhibit HLA tetramer
staining
It is inherent to the ‘‘mix-and-read’’ tetramer strategy that the
staining reaction is done with the entire tetramerization reaction
mixture including any unreacted monomer such as that of any un-
biotinylated HLA molecule. A priori, the tetramerized peptide-
HLA complexes would have a much stronger reaction with the
appropriate T cell receptor than any unreacted monomers would
have. Addressing whether the monomers could inhibit tetramer
staining, we added increasing concentrations (up to 180 Nm) of
monomers to specific T cells, incubated the cells at room
temperature for 5 minutes, and then added a fixed concentration
of tetramer (5 nM tetramer corresponding to 20 nM monomer).
In no case was any inhibition of tetramer staining observed
(Figure 6) suggesting that unreacted monomers do not compro-
mise staining with our one-pot, mix-and-read tetramers. Note, that
we have not addressed any physiological effect of peptide-HLA
monomers such as the partial activation demonstrated by Malissen
and co-workers [16].
Extending to other HLA-A*0201-peptide epitopes
To validate the generality of the ‘‘one-pot, mix-and-read’’ strategy
for tetramer production, a different set of tetramers were produced
from 3 different HLA-A*0201 EBV peptide complexes: HLA-
A*0201/LMP1125–133, HLA-A*0201/LMP2356–364 and HLA-
A*0201/LMP2416–424. PBMC’s from four different HLA-A2
positive donors were restimulated with the three different peptides
for 8 days and then stained with the tetramers (Figure 7). PBMC’s
from all four donors could be stained by one or more of the three
tetramers. In all cases, the specific staining showed baseline
separation between positive and negative populations. Three of the
donors had LMP2 356–364 specific T cells varying from about 3 to
11% of the CD8 T cells being labeled with HLA-A*0201/
LMP2 356–364. Two of the donors were positive for LMP2 416–424
with about 3 and 4% specific CD8 T cells. Only one out of four
donors was positive for LMP1125–133 with about 3% specific CD8 T
cells. The same results were obtained when the frequency of peptide
specific T cells producing IFNc was evaluated by intracellular
staining (data not shown). Thus this ‘‘one-pot, mix-and-read’’
strategy can be used to produce several different HLA-A*0201
tetramers and can directly be used for epitope screening analysis.
Extending to other HLA-alleles
We wanted to extend this application to other HLA and
peptide-HLA combinations. Complexes of two dominant CMV
Table 1. HLA preparations
HLA HC % biotinylation % folding
A*0101-BSPHAT 97 96
A*0201-HATBSP 100 95
A*0203-HATBSP 96 ND
A*0204-HATBSP 98 ND
A*0205-HATBSP 98 ND
A*0210-HATBSP 92 ND
A*0211-HATBSP 97 ND
A*0212-HATBSP 96 ND
A*0216-HATBSP 88 ND
A*0219-HATBSP 89 ND
A*1101-BSPHAT 100 ND
A*2301-HATBSP 98 ND
A*2403-HATBSP 98 ND
A*2601-HATBSP 89 ND
A*2602-HATBSP 95 ND
A*2603-HATBSP 97 ND
A*2703-BSPHAT 98 ND
A*2902-HATBSP 97 ND
A*3002-HATBSP 94 ND
A*3303-HATBSP 98 ND
A*4301-HATBSP 100 ND
A*6601-HATBSP 96 ND
A*6802-HATBSP 96 ND
A*7401-HATBSP 100 ND
A*8001-HATBSP 100 ND
B*0702-BSPHAT 100 100
B*0801-BSPHAT 97 ND
MHC HC % biotinylation % folding
B*1501-BSPHAT 97 ND
B*1509-HATBSP 94 ND
B*1513-BSPHAT 95 ND
B*1517-HATBSP 100 ND
B*1801-BSPHAT 89 ND
B*2705-BSPHAT 100 ND
B*3901-BSPHAT 94 ND
B*4001-BSPHAT 97 ND
B*4402-HATBSP 97 100
B*5101-HATBSP 100 ND
B*5201-HATBSP 100 ND
B*5301-HATBSP 100 ND
B*5401-HATBSP 98 ND
B*5801-BSPHAT 82 ND
HLA HC denotes the identity of the HLA heavy chain and the order of the
attached biotinylation (BSP) and affinity (HAT) tag. The degree of biotinylation
and the foldability is determined as stated in Materials and Methods
doi:10.1371/journal.pone.0001678.t001
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B*0702/pp65417–426, were folded. As for the HLA-A*0201, the
folding efficiency of these complexes were .96% (Table 1).
Tetramers of these complexes and the HLA-A*0201/pp65495–503
were produced and used to analyze the specificity of a CMV
response. PBMC’s from four different healthy donors were
stimulated for 8 days with a mixture of 134 overlapping 15-mer
peptides representing the entire pp65 CMV protein and
subsequently analyzed for pp65 specific responses using intracel-
lular IFNc (IC-IFNc) staining. All four donors showed a pp65
specific response, having between 16% and 46% pp65 specific
CD8 T cells (Figure 8, top panel). Using the HLA-A*0101/
pp65363–373, HLA-A*0201/pp65495–503, and HLA-B*0702/
pp65417–426 tetramers these donors were analyzed for the
specificity distribution against these three dominant pp65 T cell
epitopes (Figure 8). All three tetramers showed specific staining
and we were clearly able to differentiate the donors as responder
and non-responder to the given epitope. Two of the four donors
(Donor 1 and 4; Figure 8) stained positive for the HLA-A*0101/
pp65363–373 tetramer; one having a relative high frequency of
positive CD8 T cells and the other a very low frequency (17.6%
versus 0.06%). Two donors (Donor 1 and 2; Figure 8) stained
positive for the HLA-A*0201/pp65495–503, tetramer, both with
relative high frequencies (28.5 and 15.6%). Only donor 4 stained
positive for HLA-B*0702/pp65417–426 with 36% of the CD8 T
cells being specific for this epitope. Except for one donor, the
frequencies of tetramer positive CD8 T cells for each donor fully
covered the entire pp65 response measured by intracellular
staining for that donor. Donor 3 was not stained by any of the
three tetramers. Therefore, the pp65 specific CD8 T cells
response, must be represented by pp65 epitopes different from
the three used for tetramers.
Correlating staining with functionality
Finally,wecorrelatedtetramerstainingwithfunctionality.Though
the frequency of tetramer positive cells and IFNc producing cells
correlated nicely we wished to assure that the cells, which stained
tetramer positive, were in fact the IFNc producing cells. Three
different tetramers were produced: HLA-A*0101/pp65363–373,
HLA-A*0201/pp65495–503, and B*4401/EBNA3b657–666.T h r e e
different donors were restimulated for 8 day with the three peptides,
CMV pp65363–373, CMV pp65495–503, and EBV EBNA3b657–666,
respectively. T cells from each donor were double labeled for
tetramer and IC-IFNc (Figure 9). For all combinations, the specific
IFNc producing CD8 T cells were also stained with the relevant
tetramers. For the two donors specific for pp65363–373 and
pp65495–503, a few percentage of the tetramer labeled cells did not
produce IFNc. Since, the majority of the CMV specific CD8 T cells
produced both IFNc and TNFa and only a few percentage produced
either one or the other alone, these tetramer+,I F N c- cells were most
likely TNFa producing. Thus, the CD8 T cells stained with these
tetramers were in fact the specific CD8 T cells that produce IFNc in
response to the relevant peptide epitope.
Conclusion
In summary, we have developed a rapid ‘‘one-pot, mix-and-
read’’ strategy for tetramer production. Due to highly efficient
biotinylation, folding, and tetramerization processes, all the
preparative biochemical work normally needed during MHC
tetramer generation can be omitted and the production can run as
a fast sequential addition of the relevant reagents. Others have also
attempted to generate a high-throughput production of MHC
class I tetramers[17]. Their strategy is based on peptide exchange
of MHC complexes folded with an UV cleavable peptide. These
degradable complexes are produced in the conventional way being
Figure 2. Peptide binding affinity of biotinylated HLA-A*0201 versus non-biotinylated. The peptide binding affinities of the biotinylated
HLA-A*0201-HAT-BSP was compared to the standard truncated HLA-A*0201 molecule. The HLA-A*0201 peptide binding affinities of a panel of pox
peptides ranging from god binders (0–10 nM) over intermediary (10–100 nM) to non-binders (.1 mM) were determined in a quantitative ELISA [14].
The HC were folded with various concentrations of peptide and excess of hb2m. The KD values for each peptide MHC combination were calculated
and the results presented as means of two independent experiments with the corresponding confidence intervals.
doi:10.1371/journal.pone.0001678.g002
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this point, this peptide cleavable approach has been applied to one
human MHC class I allele (HLA-A*0201) and a mouse allele (D
b).
The broad application of their strategy is limited by the need to
define a unique UV-labile epitope for each MHC class I allele. In
contrast, our approach is based on the ability to produce fully in
vivo biotinylated and readily foldable MHC I HC. Ready-to-use
tetramers with the desired specificity and scale can be produced
within 2 days in any lab independent of special biochemical skills
or equipment. We have demonstrated the application of our ‘‘one-
pot, mix-and-read’’ strategy for 7 different MHC I restricted T
cells epitopes spanning 4 different HLA class I alleles. We have
produced an additional 37 fully biotinylated HLA-class I HC using
this strategy (Table 1). This procedure is suitable for large-scale
production of a single peptide-MHC tetramer for repeated
analysis or purification of specific T cells as well as for a small-
scale production of a larger number of different class I-peptide
complexes e.g. for a comprehensive T cell screening program.
Materials and Methods
Peptides
Peptides were synthesized by standard 9-fluorenylmethyloxy-
carbonyl (FMOC) chemistry, purified by reversed-phase high-
performance liquid chromatography (at least 80%, usually .95%
purity) (Shafer-N, Copenhagen, Denmark). Mixes of 134 15 amino
Figure 3. Binding of SA and biotinylated HLA-A*0201-peptide complexes. The folding reaction of biotinylated HLA-A*0201 was spiked with
radioactively labeled peptide. These complexes were reacted with SA at various different molar ratios in order to produce MHC-I tetramers, trimers,
dimers, and monomers. The various SA-MHC-I complexes were run on a calibrated SEC column. The eluate fraction of the SA-MHC-I complexes was
determined through radioactivity measurements. (A) Size exclusion chromatogram of 6 different stoichiometric mixtures of SA to HLA-A*0201-
peptide complex. In (B) is listed the calculated MW’s corresponding of the individual peaks of the chromatogram.
doi:10.1371/journal.pone.0001678.g003
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from PT Peptide Technologies GmbH, Germany.
Production of human MHC-I heavy chains
Recombinant MHC-I heavy chains (HC’s) have been generated
from synthetic codon optimized and truncated genes without the
transmembrane region. Sequences encoding HAT (a histidine
affinity tag) and BSP (a biotinylation tag) were fused to the 39 end
of the truncated HC gene and cloned into a pET28a+ E. coli
expression vector (Novagen). For expression, the BL21 (DE3) E. coli
strain was co-transformed with a pET28a+ vector encoding the
tagged HC’s and a pASYC vector encoding the BirA biotinylation
holoenzyme. Clones producing high amounts of HC and BirA upon
isopropylthiogalactoside (IPTG) induction were selected. 100 mg/L
biotin (Sigma) was included during the 3h IPTG induction.
Large-scale production and purification of proteins were
performed as previously described[11]. Where and how the
disulfides of the HLA heavy chains are formed is not known. The
details of protein handling may be extremely important, including
pH, temperature and time. We have not examined these
parameters, however, preparations of tetramer generating quality
were consistently generated.
Biotinylation assay
The level of biotinylation of the purified HC was examined by a
streptavidin gel-shift SDS-PAGE assay. Purified HC was incubat-
ed for 20 min at RT with a functional excess of streptavidin (SA,
each streptavidin molecule can bind four biotinylated molecules),
and analyzed by 12% polyacrylamide gel (SDS-PAGE, without
boiling the samples). SA interacts with biotinylated HC and shifts
the approximate 36 kDa monomer band to approximately
100 kDa. For comparison, serial dilutions of HC, which have
not been reacted with SA, were analyzed. The intensities of the SA
Figure 4. Tetramer staining comparison to pentamer. PBMC from a healthy donor were stimulated for 8 day with the pp65495–503 peptide and
stained with APC labeled anti-CD8 and PE-labeled HLA-A*0201-pp65495–503 tetramer (right panel) or with PE-labeled HLA-A*0201-pp65495–503
pentamer (left panel). The dot plot shows the gated CD8 T cells. Numbers in the upper right quadrant of each plot are the percentage of epitope
specific CD8 T cells. The fluorescence intensity (FI) of the staining of the positive and negative population is given in the upper and lower right
quadrant, respectively.
doi:10.1371/journal.pone.0001678.g004
Figure 5. Titration of complex concentration for tetramer
production. Three different concentrations of HLA-A*0201-
pp65495–503 complexes were folded (50, 100, and 200 nM) and
tetramers were produced from these. PBMC from a CMV pp65495–503
responsive donor (3.5% specific CD8 T cells) were stained with a
titration of each of the three tetramer productions. The x-axis is the
actual calculated concentration of tetramers in the cell staining reaction.
The results are depicted as the relative fluorescence intensity (FI signal
of the positive population/FI signal of the negative population).
doi:10.1371/journal.pone.0001678.g005
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pp65495–503 peptide. They were washed and adjusted to a final concentration of 2.5 million cells/ml containing the indicated concentration of CMV
pp65495–503/HLA-A*0201 monomer. After 5 min incubation at room temperature, a final concentration of 5 nM CMV pp65495–503/HLA-A*0201
tetramer was added. The cells were further stained for CD8 and analyzed by flow cytometry as described in materials and methods.
doi:10.1371/journal.pone.0001678.g006
Figure 7. HLA-A*0201-tetramer screening of EBV reactive donors. PBMC from four healthy donors were each re-stimulated for 8 day with
three different EBV peptides, LMP1125–133, LMP2356–364, or LMP2416–424, and stained with both HLA-A*0201-LMP1125–133 (top panel, HLA-A*0201-
LMP2356–364 (middle panel) and HLA-A*0201-LMP2416–424 tetramers (bottom panel). The dot plot shows gated CD8 T cells and the percentage of
tetramer labeled CD8 T cells are given in the upper right quadrant of each plot.
doi:10.1371/journal.pone.0001678.g007
One-Pot, Mix-and-Read Tetramer
PLoS ONE | www.plosone.org 8 February 2008 | Volume 3 | Issue 2 | e1678reacted and non-reacted HC bands were determined by
densitometric analysis using 1D Gel Analysis software (Kodak
Digital Science). The percentage of biotinylated HC could be
calculated from the ratio of intensity of the HC band of the sample
without SA compared to the sample with excess SA.
Quantitative measurement of peptide MHC-I complex
formation
The peptide binding affinity of biotinylated versus non-biotiny-
lated HLA-A*0201 were compared using our previously described
quantitative ELISA assay[14]. Briefly, peptide-MHC-I complexes
were folded at 18uC for 48 hours with a constant concentration of
hß2m and a titration of peptide concentrations. The complex
formation was measured with a sandwich ELISA using the
conformationally sensitive monoclonal antibody, W6/32, for
capturing peptide-MHC monomers and a HRP conjugated
polyclonal rabbit anti-human ß2m antibody (DAKO) for detection
of correctly folded complexes. The ELISA was developed with
EnVision
TM (DAKO #K4003). MHC-I concentration was mea-
sured by spectrophotometric analysis in a Microplate Scanning
Spectrophotometer, Discovery HT-R (BIO-TEK Instruments). A
Figure 8. Screening for CMV specific T cells with three different Class I-tetramers. PBMC from 4 healthy CMV pp65 responding donor were
stimulated for 8 day with a mixture of 15 amino acid long overlapping peptides spanning the entire pp65 protein. The cells were analyzed pp65
specific responses using the IC-IFNc assay and stained for CD8, CD69 and intracellular IFNc (top panel). The donors were screened for HLA-A*0101
restricted pp65363–373, the HLA-A*0201 restricted pp65495–503, and the HLA-B*0702 restricted pp65417–426 specific T cells. Staining the cells with CD8
and each of the three tetramers, HLA-A*0101-pp65363–373, HLA-A*0201-pp65495–503, and HLA-B*0702-pp65417–426. The dot plot shows the gated CD8
T cells. Numbers in the upper right quadrant of each plot are the percentage of epitope specific CD8 T cells.
doi:10.1371/journal.pone.0001678.g008
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as reference for conversion of absorbance data to concentrations. A
sigmoid fit (y=Bmax*x/(KD+x) of each peptide titration curve on
semi logarithmic coordinate scales provides Bmax and KD values.
Size exclusion chromatography of peptide-MHC
tetramers
The tetramerization ofpeptide-MHC-I monomercomplexes with
SA was visualized by Superdex 200 (Amersham Biosciences)
chromatography. Iodinated (
125I) peptide-MHC-I monomers were
generated using radioactively labeled peptides, and subsequently
used to spike a preparation of unlabeled peptide-MHC-I monomers.
The spiked peptide-MHC-I complexes were then reacted with
various stoichiometric ratios of SA. A 100 mls a m p l eo fM H C - S A
complexes were analyzed on a 23 ml pre-packed and calibrated
Superdex 200 SEC column; 200 ml fractions were collected, and
analyzed by gamma-spectrometry (Cobra 5010, Packard).
‘‘One-pot’’ MHC tetramer production
Peptide-MHC-I monomer complexes were generated by
diluting the HC (typical stock concentration 15–40 mM)) 100-fold
into a reaction buffer containing 50 mM tris-maleate pH 6.6,
0.1% pluronic F86 NF (BASF, a surfactant compatible with
cellular use), a 20-fold molar excess of ß2m, and 50-fold molar
excess of peptide. The mixture was vortex’ed briefly and incubated
at 18uC for 48 hours. Streptavidin-R-Phycoerythrin (SA-PE,
Becton Dickinson) was then added (sequentially in 10 small
aliquots over 90 min) at a molar ratio of four MHC to one SA.
This reaction mixture containing tetramers was stored at 4uC.
Cell lines and culture condition
Buffy coats were obtained from healthy volunteer Danish
donors from The Blood Bank at the national Hospital (Copenha-
gen, Denmark). Peripheral blood mononuclear cells (PBMC) were
isolated by density gradient centrifugation using Ficoll-Paque (GE-
healthcare). To stimulate specific CTL, 2 mg/ml peptide were
added to the PBMC and incubated for 8–9 days in Xvivo15
(Lonza) supplemented with 5% autologous serum. IL2 at 50 U/ml
were added at day 1, 4, and 6. Dendritic cells (DC) were used as
APC. PBMC were adhered for 2 h at 37uC in 24-well plates.
Adherent cells were cultured for 9 days in Xvivo15 with 5% AB
serum, 100 ng/ml GM-CSF, and 100 ng/ml IL4. At day 7 the
DC were activated with a mixture of 10 ng/ml TNFa, 5 ng/ml
IL1b, 20 ng/ml IL6, and 1 mg/ml PGE2.
Tetramer staining
PBMCorTcells,harvestedday8,werealiquotedat2*10
5/wellin
a 96-well round bottom microtiter well. The cells were pelleted and
resuspended in 25 ml tetramer, incubated for 20 min at RT followed
by 30 min incubation with anti CD8-APC (Pharmingen) at 4uC.
After two washes the cells were analyzed on a FACScalibur.
Intracellular staining for IFNc
DC’s were pulsed with or without peptide for 1 h and added to
the T cells. The cells were incubated for 3h with Brefeldin A at
37uC. Subsequently, staining for CD8, CD69 and intracellular
IFNc was carried out according to the Fast Immune protocol
(Pharmingen). In some cases prior to the Fast Immune staining the
cells were stained with tetramers as described above. The cells
were analyzed on a FACScalibur.
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